JDRF, PureTech Try Nonprofit Ownership To Fill Funding Gap For Diabetes Tech
This article was originally published in The Gray Sheet
Call it venture philanthropy with a twist: If all goes as planned, the Juvenile Diabetes Research Foundation will co-own a series of companies dedicated to type 1 diabetes treatments without violating tax code, thanks to a structure created by Boston’s PureTech Ventures.
You may also be interested in...
Merck, Lilly and Pfizer team up with PureTech Ventures to form Enlight Biosciences, a novel start-up developing next-generation technologies that promise to speed the way drugs are found and developed.
The latest accelerated approval withdrawals in the US are milestones for accountability in the program – most notably with the withdrawal of an antimicrobial with confirmatory studies more than a decade overdue.
Based on promising Phase II data, two companies in South Korea are moving ahead with late-stage development in the gout space, with JW Pharmaceutical getting approvals to begin a multinational Phase III trial for epaminurad, while LG Chem has recently submitted an application for a Phase III program with its contender tigulixostat.